Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig monotherapy or pumitamig + ipilimumab in first-line advanced or unresectable hepatocellular carcinoma
CTR20261876Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig, ipilimumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started May 2026; status: active.
02
Drugs
pumitamigipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20261876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261876.